Ticker > Company >

Nureca Ltd. share price

Nureca Ltd.

NSE: NURECA BSE: 543264 SECTOR: Medical Equipment/Supplies/Accessories  92.78 K   298   22

262.20
+10.25 (4.07%)
BSE: 04 Sep 04:01 PM

Price Summary

Today's High

₹ 271.5

Today's Low

₹ 254

52 Week High

₹ 447

52 Week Low

₹ 198

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

262.2 Cr.

Enterprise Value

217.53 Cr.

No. of Shares

1 Cr.

P/E

0

P/B

1.36

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  193.03

CASH

46.2 Cr.

DEBT

1.52 Cr.

Promoter Holding

64.33 %

EPS (TTM)

₹  -1.31

Sales Growth

21.29%

ROE

-0.35 %

ROCE

0.34%

Profit Growth

72.65 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Nureca Ltd.

Dr. Trust Dr. Physio Trumom

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year21.29%
3 Year-23.45%
5 Year2.89%

Profit Growth

1 Year72.65%
3 Year-124.52%
5 Year-163.62%

ROE%

1 Year-0.35%
3 Year-1.94%
5 Year14.27%

ROCE %

1 Year0.34%
3 Year-2.12%
5 Year19%

Debt/Equity

0.0079

Price to Cash Flow

-14.14

Interest Cover Ratio

0.5874

CFO/PAT (5 Yr. Avg.)

0.341584589906738

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 64.33 0.00
Mar 2025 64.30 0.00
Dec 2024 64.06 0.00
Sep 2024 63.77 0.00
Jun 2024 63.24 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 77.3336 days.
  • Company has a healthy liquidity position with current ratio of 17.6592.
  • The company has a high promoter holding of 64.33%.

 Limitations

  • The company has shown a poor profit growth of -124.520575663308% for the Past 3 years.
  • The company has shown a poor revenue growth of -23.4482439415132% for the Past 3 years.
  • Company has a poor ROE of -1.9422% over the past 3 years.
  • Company has a poor ROCE of -2.12333333333333% over the past 3 years
  • Company has negative cash flow from operations of -18.548.
  • The company has a low EBITDA margin of 3.23886% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 153.0806.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 23.31 32.37 27.21 31.75 34.32
Total Expenditure 26.23 35.03 31.94 31.18 35.4
Operating Profit -2.91 -2.66 -4.73 0.57 -1.08
Other Income 5.82 3.21 1.52 2 2.59
Interest 0.13 0.25 0.14 0.59 0.2
Depreciation 0.61 0.57 0.49 0.48 0.48
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.16 -0.27 -3.85 1.5 0.83
Tax 0.97 0.38 -0.56 -0.57 0.28
Profit After Tax 1.2 -0.65 -3.29 2.07 0.55
Adjusted EPS (Rs) 1.2 -0.65 -3.29 2.07 0.55

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 213.33 255.55 111.9 94.52 114.64
Total Expenditure 151.65 199.78 127.29 105.67 124.64
Operating Profit 61.68 55.77 -15.39 -11.15 -10
Other Income 2.82 7.72 7.17 10.58 12.81
Interest 1.6 0.73 0.43 0.46 1.12
Depreciation 0.41 1.43 2.3 2.24 2.15
Exceptional Items 0 0 0 0 0
Profit Before Tax 62.49 61.33 -10.96 -3.27 -0.46
Tax 15.96 16.02 -2.54 -0.83 0.21
Net Profit 46.53 45.31 -8.42 -2.44 -0.67
Adjusted EPS (Rs.) 46.53 45.31 -8.42 -2.44 -0.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10 10 10 10 10
Total Reserves 153.29 193.74 185.26 182.86 182.48
Borrowings 0.78 0 0 0.33 1.05
Other N/C liabilities 2.46 3.59 0.11 -2.5 -1.06
Current liabilities 33.88 45.14 8.62 9.27 10.44
Total Liabilities 200.41 252.48 203.98 199.96 202.91
Assets
Net Block 3.37 9.78 8.08 6.33 7.8
Capital WIP 0 0 0 0 0
Intangible WIP 0.3 0.42 0 0 0
Investments 0.82 1.31 3.06 3.06 3.06
Loans & Advances 0.09 0.26 1.61 0.92 3.86
Other N/C Assets 0 1.95 7.24 0 3.82
Current Assets 195.84 238.76 184 189.66 184.38
Total Assets 200.41 252.48 203.98 199.96 202.91
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 62.49 61.33 -10.96 -3.27 -0.46
Adjustment 0.09 -3.79 -3.64 -6.98 -8.2
Changes in Assets & Liabilities -12.42 -37.76 30.78 5.76 -8.86
Tax Paid -15.07 -17.96 -4.14 1.49 -1.03
Operating Cash Flow 35.1 1.83 12.05 -3 -18.55
Investing Cash Flow -110.48 -3.37 -18.3 17.84 8.56
Financing Cash Flow 92.34 -7.3 -1.51 -1.28 -0.79
Net Cash Flow 16.96 -8.84 -7.76 13.56 -10.77

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 63.24 63.77 64.06 64.30 64.33
aryan goyal 3.76 - 3.68 - 7.23
nectar biopharma private ... - 0.54 0.61 0.61 0.61
payal goyal 27.98 - 28.10 - 24.60
saurabh goyal 31.49 - 31.67 - 31.89
aryan goyal - 3.63 - 7.23 -
payal goyal - 27.98 - 24.60 -
saurabh goyal - 31.62 - 31.86 -
PARTICULARS Sep 2022% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 30.00 36.23 35.94 35.70 35.67
llp - 0.02 0.02 - 0.02
nisarg vakharia - - - 1.78 1.85
viral amal parikh - - - - 1.08
hornbill orchid india fun... 1.44 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2019
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY22

Company News

Nureca informs about filing of scheme 24 Jul, 1:30 PM Nureca Ltd. - Quaterly Results 15 Jul, 5:44 PM Nureca Ltd. - Quaterly Results 15 Jul, 5:44 PM Nureca Ltd. - Quaterly Results 15 Jul, 5:44 PM Nureca Ltd. - Quaterly Results 5 May, 9:03 PM Nureca Ltd. - Quaterly Results 5 May, 9:03 PM Nureca expands quick commerce reach with Dr Trust products now available on Swiggy Instamart 30 Apr, 11:41 AM Nureca gets nod to set up new manufacturing facility in Punjab 22 Apr, 12:20 PM Nureca’s manufacturing arm completes annual registration with USFDA 14 Apr, 9:09 AM Nureca informs about press release 12 Apr, 4:53 PM Nureca gets nod to purchase land in India 25 Feb, 12:12 PM Nureca informs about disclosure 31 Jan, 5:20 PM Nureca Ltd. - Quaterly Results 24 Jan, 6:16 PM Nureca Ltd. - Quaterly Results 24 Jan, 6:16 PM Nureca Ltd. - Quaterly Results 24 Jan, 6:16 PM Nureca informs about appoinemnt of additional directors 21 Nov, 1:35 PM Nureca enters into distribution agreement with Zepto 16 Nov, 3:20 PM Nureca Ltd. - Quaterly Results 24 Oct, 5:47 PM Nureca Ltd. - Quaterly Results 24 Oct, 5:47 PM Nureca informs about closure of trading window 26 Sep, 4:26 PM Nureca enters into distribution agreement to make products available on commerce platform 17 Sep, 12:42 PM Nureca Ltd. - Quaterly Results 5 Aug, 5:11 PM Nureca Ltd. - Quaterly Results 5 Aug, 5:11 PM Nureca Ltd. - Quaterly Results 5 Aug, 5:11 PM Nureca Ltd. - Quaterly Results 15 May, 11:51 AM Nureca Ltd. - Quaterly Results 15 May, 11:51 AM Nureca Ltd. - Quaterly Results 15 May, 11:51 AM Nureca informs about compliance certificate 9 Apr, 2:17 PM Nureca’s Dr Trust recognized as ‘Well Known Trademark’ by Indian Trademark Registry 2 Apr, 6:07 PM Nureca informs about press release 1 Mar, 1:24 PM Nureca informs about press release 8 Feb, 5:02 PM Nureca Ltd. - Quaterly Results 7 Feb, 5:24 PM Nureca Ltd. - Quaterly Results 7 Feb, 5:24 PM Nureca Ltd. - Quaterly Results 7 Feb, 5:24 PM Nureca Ltd. - Quaterly Results 4 Nov, 5:17 PM Nureca Ltd. - Quaterly Results 4 Nov, 5:17 PM Nureca Ltd. - Quaterly Results 4 Nov, 5:17 PM Nureca Ltd. - Quaterly Results 10 Aug, 5:55 PM Nureca Ltd. - Quaterly Results 10 Aug, 5:55 PM Nureca Ltd. - Quaterly Results 23 May, 8:01 PM Nureca Ltd. - Quaterly Results 23 May, 8:01 PM Nureca informs about secretarial compliance report 17 May, 5:08 PM Nureca Ltd. - Quaterly Results 3 Feb, 6:28 PM Nureca Ltd. - Quaterly Results 3 Feb, 6:28 PM Nureca informs about board meeting 28 Jan, 12:33 PM Nureca informs about disclosure of related party transactions 26 Nov, 3:20 PM Nureca Ltd. - Quaterly Results 11 Nov, 6:38 PM Nureca Ltd. - Quaterly Results 11 Nov, 6:38 PM Nureca’s arm obtains ISO 13485:2016 certification for Indian medical device facility 8 Oct, 3:06 PM Nureca submits press release 8 Oct, 12:21 PM

Nureca Ltd. Stock Price Analysis and Quick Research Report. Is Nureca Ltd. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Nureca Ltd.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Nureca Ltd. has a PE ratio of -198.382913806255 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Nureca Ltd. has ROA of -0.3316% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Nureca Ltd. has a Current ratio of 17.6592.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Nureca Ltd. has a ROE of -0.3467%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Nureca Ltd. has a Debt to Equity ratio of 0.0079 which means that the company has low proportion of debt in its capital.

  • Sales growth: Nureca Ltd. has reported revenue growth of 21.2852% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Nureca Ltd. for the current financial year is -8.72470341939986%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Nureca Ltd. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Nureca Ltd. is Rs -1.311. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Nureca Ltd. in Ticker for free. Also, one can get the intrinsic value of Nureca Ltd. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Nureca Ltd. FAQs

Q1. What is Nureca Ltd. share price today?
Ans: The current share price of Nureca Ltd. is Rs 260.08.

Q2. What is the market capitalisation of Nureca Ltd.?
Ans: Nureca Ltd. has a market capitalisation of Rs 260.0845514 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Nureca Ltd.?
Ans: The PE ratio of Nureca Ltd. is -198.382913806255 and the P/B ratio of Nureca Ltd. is 1.34737068961051, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Nureca Ltd. share?
Ans: The 52-week high share price of Nureca Ltd. is Rs 447.5, and the 52-week low share price of Nureca Ltd. is Rs 203.62.

Q5. Does Nureca Ltd. pay dividends?
Ans: Currently, Nureca Ltd. does not pay dividends. Dividend yield of Nureca Ltd. is around 0%.

Q6. What are the face value and book value of Nureca Ltd. shares?
Ans: The face value of Nureca Ltd. shares is Rs 10, while the book value per share of Nureca Ltd. is around Rs 193.0278. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Nureca Ltd.?
Ans: Nureca Ltd. has a total debt of Rs 1.523 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Nureca Ltd.?
Ans: The ROE of Nureca Ltd. is -0.3467% and ROCE of Nureca Ltd. is 0.3383%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Nureca Ltd. a good buy for the long term?
Ans: The Nureca Ltd. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Nureca Ltd. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Nureca Ltd. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Nureca Ltd.’s financials?
Ans: You can review Nureca Ltd.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Nureca Ltd.
X